Nirsevimab Immunization Outcomes in the First Two Years
Nirsevimab, a long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV), was associated with a substantial reduction ...
Nirsevimab, a long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV), was associated with a substantial reduction ...
In a groundbreaking study, researchers have examined the critical role of early intravenous immunoglobulin (IVIG) administration in improving outcomes for ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine